pharmaphorum

Germany first in EU to get Novartis' SMA gene therapy, costing almost 2m euros

Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) in Germany at the start of July priced at 1,945,000 euros, and says ...
pharmaphorum

Roche puts pressure on SMA rivals with new FDA approval

Roche and PTC Therapeutics' Evrysdi for spinal muscular atrophy (SMA) has been approved by the FDA for younger children with the rare disease, extending its use to include infants less than two months ...
IEEE

Wrist Assisting Soft Wearable Robot With Stretchable Coolant Vessel Integrated SMA Muscle

Abstract: This article proposes a shape memory alloy (SMA)-based artificial muscle that has an active cooling system. An SMA coil spring is embedded into a stretchable coolant vessel, which allows ...
IEEE

Design of Compact High-Isolation Four-Way Power Combiners

Abstract: In this paper, the design methods for four-way power combiners based on eight-port and nine-port mode networks are proposed. The eight-port mode network is fundamentally a two-stage binary ...